COVID-19 Vaccine (recombinant, adjuvanted)

This medicine is authorised for use in the European Union.


Nuvaxovid is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older.

Nuvaxovid contains a version of a protein found on the surface of SARS-CoV-2 (the spike protein), which has been produced in the laboratory.

This EPAR was last updated on 07/01/2022

Authorisation details

Product details
Agency product number
Active substance
SARS-CoV-2 recombinant spike protein
International non-proprietary name (INN) or common name
COVID-19 Vaccine (recombinant, adjuvanted)
Therapeutic area (MeSH)
COVID-19 virus infection
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Conditional approvalConditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see Conditional marketing authorisation.

Publication details
Marketing-authorisation holder
Novavax CZ, a.s.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Bohumil 138
Jevany, 28163

Product information

20/12/2021 Nuvaxovid - EMEA/H/C/005808 -


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group


Therapeutic indication

Nuvaxovid is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Assessment history

Safety updates

How useful was this page?

Add your rating
20 ratings
4 ratings
1 rating
2 ratings
15 ratings